ZNTL vs. ZVRA, PRME, BCYC, EOLS, REPL, CMPS, RGNX, ARCT, CMPX, and ETON
Should you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Zevra Therapeutics (ZVRA), Prime Medicine (PRME), Bicycle Therapeutics (BCYC), Evolus (EOLS), Replimune Group (REPL), COMPASS Pathways (CMPS), REGENXBIO (RGNX), Arcturus Therapeutics (ARCT), Compass Therapeutics (CMPX), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry.
Zentalis Pharmaceuticals vs. Its Competitors
Zevra Therapeutics (NASDAQ:ZVRA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.
35.0% of Zevra Therapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 1.9% of Zentalis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Zevra Therapeutics has a net margin of 4.33% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Zentalis Pharmaceuticals' return on equity of -51.62% beat Zevra Therapeutics' return on equity.
Zevra Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500.
Zevra Therapeutics presently has a consensus target price of $23.71, indicating a potential upside of 205.99%. Zentalis Pharmaceuticals has a consensus target price of $8.20, indicating a potential upside of 450.34%. Given Zentalis Pharmaceuticals' higher possible upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Zevra Therapeutics.
In the previous week, Zevra Therapeutics had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 4 mentions for Zevra Therapeutics and 2 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.65 beat Zevra Therapeutics' score of 1.33 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.
Zevra Therapeutics has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Zevra Therapeutics beats Zentalis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Zentalis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zentalis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ZNTL) was last updated on 9/14/2025 by MarketBeat.com Staff
